rhPSMA (radiohybrid PSMA) is a prostate specific membrane antigen labeled with two potentially radioactive atoms, but under two forms in which only one of the two atoms is radioactive. The molecules offer two labeling sites for radionuclides, a silicon-fluorine acceptor (SiFA) site for 18F-labeling via isotopic exchange and a chelator for radiometallation with 177Lu.
This molecule will have the same profile as any other standard PSMA tracer with target indications identical to all other PSMA targeting tracers under development.
The compound entered Phase I/II clinical study in April 2022.
Radiation Type: beta electrons (β–)